

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**LANSEN PHARMACEUTICAL HOLDINGS LIMITED**

**朗生醫藥控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 503)**

**DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of Lansen Pharmaceutical Holdings Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on 28 February 2022 (Monday) for the purpose of, amongst other matters, approving the publication of the annual results of the Company and its subsidiaries for the year ended 31 December 2021.

By order of the Board  
**Lansen Pharmaceutical Holdings Limited**  
**Pang Kai Fai**  
*Company Secretary*

Hong Kong, 16 February 2022

*As at the date of this announcement, the executive managing Director is Mr. Chen Li; the non-executive Directors are Mr. Wu Zhen Tao, Mr. Stephen Burnau Hunt and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Yeung Tak Bun, Allen and Ms. Chan Ching Har, Eliza.*